search
Back to results

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

Primary Purpose

Diabetes Mellitus, Hypertension, Metabolic Disease

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Orlistat
Placebo
Sponsored by
Jack Yanovski
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus focused on measuring Dyslipidemia, Race, Body Fat, Visceral Fat, Sleep Apnea, Fat-Soluble Vitamins, Type 2 Diabetes, Obesity, Childhood Obesity

Eligibility Criteria

12 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA: Good general health. Individuals taking medications for obesity-related comorbid conditions will not be excluded. Obesity: body mass index for age and triceps skinfold above the 95th percentile (determined by NHANES I age-, sex-, and race- specific data). All subjects will be required to be over 60 kg in body weight. Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes, impaired glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia (defined as a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total cholesterol greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting triglycerides greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range with negative hepatitis studies) or sleep apnea documented by a sleep study. Age 12 to 17 years at the start of the study. For girls with childbearing potential, a negative pregnancy test before taking and while taking study medication. Sexually active females must be using an effective form of birth control. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. Race of all four grandparents self-identified as either all Caucasian or all African American. EXCLUSION CRITERIA: Volunteers will be excluded (and referred to non-experimental treatment programs) for the following reasons: Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma not requiring continuous medication or sleep apnea-related disorders); Adolescent girls who are pregnant, who are currently nursing an infant, or who are having unprotected intercourse; Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study; Subjects who regularly use prescription medications unrelated to the complications of obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before starting study medication. The use of over-the-counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication for at least 3 months prior to study entry may be eligible; Recent use (within six months) of anorexiant medications for the purpose of weight reduction; Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants, non-detachable electronic or electromechanical devices such as infusion pumps, nerve stimulators, bone growth stimulators, etc. that are contraindications). For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals with documented G6PD deficiency will be excluded. INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS: Volunteers will qualify for inclusion if they meet the following criteria: Good general health. Age 12-17 years at study entry. Body mass index (BMI) for age above the 5th percentile and below 85th percentile, which is considered normal weight by CDC growth chart standards. For females with childbearing potential, a negative pregnancy test at initial evaluation. Race of all four grandparents self-identified as either all Caucasian or all African American. EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS: Volunteers will be excluded for the following reasons: Presence of past or present medical problems which would impair performance during the exercise tests; Females who are pregnant, or who are currently nursing an infant; Individuals who have, or whose parent or guardian has, current substance abuse or a psychiatric disorder or other condition that in the opinion of the investigators would impede competence or possibly hinder completion of the study; Recent weight change of more than 3% of body weight in the past two months; Recent use (within six months) of anorexiant medications for the purpose of weight reduction; Physical impairments that would prevent completion of either the walk/run test or the cycle test.

Sites / Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Orlistat

Arm Description

Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program

Orlistat 120 mg TID for 6 months plus a behavioral weight loss program

Outcomes

Primary Outcome Measures

Change in BMI Standard Deviation Score
Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190.

Secondary Outcome Measures

Change in Body Weight
Weight in kg
Change in Body Mass Index
BMI is calculated in kg/m2. Change from baseline to 6 months of treatment
Change in Body Fat (kg)
body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA)
Effect of Race on Change in Weight (kg)
Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black)

Full Information

First Posted
November 3, 1999
Last Updated
November 15, 2012
Sponsor
Jack Yanovski
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Roche Pharma AG
search

1. Study Identification

Unique Protocol Identification Number
NCT00001723
Brief Title
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Official Title
Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
May 1998 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jack Yanovski
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Roche Pharma AG

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals with the onset of obesity during childhood or adolescence are at an increased risk of obesity-related, diseases, both during adolescence and later in adult life. African American girls and women are at an increased risk for obesity, and have substantial rates of obesity-related diseases and causes of death. Further, many African American adult women fail to respond to many of the therapeutic approaches used to treat obesity. At present there are no medical therapies proven effective for the correction of severe obesity in children or adolescents. One medication that may have a favorable risk-benefit ratio in pediatric populations is Orlistat (Xenical, Hoffmann LaRoche). Orlistat works by preventing the action of enzymes in the digestive process, interfering with the absorption of approximately 1/3 of the fat eaten in the diet. Xenical appears to be effective for reducing weight and obesity-associated diseases in obese adults. Researchers propose to determine the safety, tolerability, and efficacy of Xenical in 12-17 year old severely obese African American and Caucasian children and adolescents who have one or more obesity-related disease (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin resistance, impaired glucose tolerance, or Type 2 diabetes).
Detailed Description
Obesity is a condition affecting one-third of the adult U.S. population and is a major risk factor for the development of Type 2 diabetes, hyperlipidemia, hypertension, and other cardiovascular and respiratory disorders. Individuals with the onset of obesity during childhood or adolescence are at increased risk for obesity-related, comorbid conditions, both during adolescence and later in life. African American girls and women are at particular risk for obesity, and have substantial rates of obesity-related morbidity and mortality. Further, African American adult women have a less satisfactory response to many therapeutic approaches used to treat obesity. At present, there are no medical therapies proven effective for the amelioration of severe obesity in children or adolescents. One medication that may have a favorable risk-benefit ratio in pediatric populations is orlistat (Xenical(Trademark), Hoffmann LaRoche). Orlistat acts by inhibiting gastrointestinal lipases, interfering with the absorption of approximately 1/3 of ingested dietary fat. Orlistat appears to be effective for reducing weight and obesity-associated comorbidities in obese adults. We propose to determine the safety, tolerability, and efficacy of orlistat in 12-17 year-old severely obese African American and Caucasian children and adolescents who have one or more obesity-related comorbidity (hypertension, hyperlipidemia, sleep apnea, hepatic steatosis, insulin-resistance, impaired glucose tolerance, or Type 2 diabetes). Under this protocol, we have conducted an open-label pilot study of orlistat in twenty subjects, suggesting orlistat has a similar side effect profile in adolescents as in adults. We wish to determine the safety and efficacy of orlistat in reducing obesity-related comorbidities using a randomized, double-blind, placebo-controlled clinical trial. All study participants will be enrolled in a psycho-educational weight loss program that includes nutrition education, cognitive-behavioral self-monitoring strategies, and promotion of physical activity. We will also study the effects of orlistat on fat preferences, and study the influence of genetic variables on energy expenditure and weight loss during treatment. A group of healthy, non-overweight children and adolescents will complete questionnaires and exercise studies as a control group for interpretation of results in overweight children and adolescents, but will not undergo phlebotomy or receive any medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Keywords
Dyslipidemia, Race, Body Fat, Visceral Fat, Sleep Apnea, Fat-Soluble Vitamins, Type 2 Diabetes, Obesity, Childhood Obesity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
Arm Title
Orlistat
Arm Type
Experimental
Arm Description
Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
Intervention Type
Drug
Intervention Name(s)
Orlistat
Other Intervention Name(s)
Xenical (orlistat)capsules
Intervention Description
Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo capsule
Intervention Description
Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Primary Outcome Measure Information:
Title
Change in BMI Standard Deviation Score
Description
Body Mass index standard deviation score calculated for age and sex according to Centers for Disease Control standards. See: Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; (246): 1-190.
Time Frame
baseline to 6 months
Secondary Outcome Measure Information:
Title
Change in Body Weight
Description
Weight in kg
Time Frame
baseline to 6 months
Title
Change in Body Mass Index
Description
BMI is calculated in kg/m2. Change from baseline to 6 months of treatment
Time Frame
baseline to 6 months
Title
Change in Body Fat (kg)
Description
body fat distribution measures obtained from Dual-energy X-ray Absorptiometry (DEXA)
Time Frame
baseline to 6 months
Title
Effect of Race on Change in Weight (kg)
Description
Difference in change of weight in kg according to race (Non-Hispanic White versus Non-Hispanic Black)
Time Frame
baseline to 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: Good general health. Individuals taking medications for obesity-related comorbid conditions will not be excluded. Obesity: body mass index for age and triceps skinfold above the 95th percentile (determined by NHANES I age-, sex-, and race- specific data). All subjects will be required to be over 60 kg in body weight. Evidence for a quantifiable obesity-related comorbidity. Examples include: systolic or diastolic hypertension (determined by age-specific charts); frank Type 2 diabetes, impaired glucose tolerance assessed by oral glucose tolerance testing; hyperinsulinemia (defined as a fasting insulin greater than 15 mIU/mL); significant hyperlipidemia (total cholesterol greater than 200 mg/dL, LDL cholesterol greater than 129 mg/dL or fasting triglycerides greater than 200 mg/dL); hepatic steatosis (SGPT or SGOT above normal range with negative hepatitis studies) or sleep apnea documented by a sleep study. Age 12 to 17 years at the start of the study. For girls with childbearing potential, a negative pregnancy test before taking and while taking study medication. Sexually active females must be using an effective form of birth control. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended. Race of all four grandparents self-identified as either all Caucasian or all African American. EXCLUSION CRITERIA: Volunteers will be excluded (and referred to non-experimental treatment programs) for the following reasons: Presence of renal, hepatic (other than obesity-related steatosis), gastrointestinal, most endocrinologic (e.g., Cushing syndrome), or pulmonary disorders (other than either asthma not requiring continuous medication or sleep apnea-related disorders); Adolescent girls who are pregnant, who are currently nursing an infant, or who are having unprotected intercourse; Individuals who have, or whose parent or guardians have, current substance abuse or a psychiatric disorder or other condition which, in the opinion of the investigators, would impede competence or compliance or possibly hinder completion of the study; Subjects who regularly use prescription medications unrelated to the complications of obesity. Oral contraceptive use will be permitted, provided the contraceptive has been used for at least two months before starting study medication. The use of over-the-counter and prescription medications will be reviewed on a case-by-case basis; depending on the medication, subjects who have continued to take prescription medication for at least 3 months prior to study entry may be eligible; Recent use (within six months) of anorexiant medications for the purpose of weight reduction; Inability to undergo MRI (e.g., volunteers with metal within their bodies including cardiac pacemakers, neural pacemakers, aneurysmal clips, shrapnel, ocular foreign bodies, cochlear implants, non-detachable electronic or electromechanical devices such as infusion pumps, nerve stimulators, bone growth stimulators, etc. that are contraindications). For pilot study participants, hypersensitivity or allergy to methylene blue. Individuals with documented G6PD deficiency will be excluded. INCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS: Volunteers will qualify for inclusion if they meet the following criteria: Good general health. Age 12-17 years at study entry. Body mass index (BMI) for age above the 5th percentile and below 85th percentile, which is considered normal weight by CDC growth chart standards. For females with childbearing potential, a negative pregnancy test at initial evaluation. Race of all four grandparents self-identified as either all Caucasian or all African American. EXCLUSION CRITERIA: HEALTHY CONTROL CHILDREN AND ADOLESCENTS: Volunteers will be excluded for the following reasons: Presence of past or present medical problems which would impair performance during the exercise tests; Females who are pregnant, or who are currently nursing an infant; Individuals who have, or whose parent or guardian has, current substance abuse or a psychiatric disorder or other condition that in the opinion of the investigators would impede competence or possibly hinder completion of the study; Recent weight change of more than 3% of body weight in the past two months; Recent use (within six months) of anorexiant medications for the purpose of weight reduction; Physical impairments that would prevent completion of either the walk/run test or the cycle test.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jack A Yanovski, M.D.
Organizational Affiliation
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Clinical Center, 9000 Rockville Pike
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
8022039
Citation
Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994 Jul 20;272(3):205-11. doi: 10.1001/jama.272.3.205.
Results Reference
background
PubMed Identifier
7627244
Citation
Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjostrom L, van der Veen EA. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord. 1995 Apr;19(4):221-6.
Results Reference
background
PubMed Identifier
1406836
Citation
Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med. 1992 Nov 5;327(19):1350-5. doi: 10.1056/NEJM199211053271904.
Results Reference
background
PubMed Identifier
15956632
Citation
Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005 Jun 15;293(23):2873-83. doi: 10.1001/jama.293.23.2873. Erratum In: JAMA. 2005 Sep 28;294(12):1491.
Results Reference
background
PubMed Identifier
15112907
Citation
McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, Van Hubbard S, Yanovski JA. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 2004 Mar;17(3):307-19. doi: 10.1515/jpem.2004.17.3.307.
Results Reference
result
PubMed Identifier
12126214
Citation
McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 Jul;22(7):814-22. doi: 10.1592/phco.22.11.814.33627.
Results Reference
result
PubMed Identifier
12105286
Citation
McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002 Jul;10(7):642-50. doi: 10.1038/oby.2002.87.
Results Reference
result
PubMed Identifier
33059389
Citation
Schvey NA, Shank LM, Tanofsky-Kraff M, Ramirez S, Altman DR, Swanson T, Rubin AG, Kelly NR, LeMay-Russell S, Byrne ME, Parker MN, Broadney MM, Brady SM, Yanovski SZ, Yanovski JA. Weight-based teasing in youth: Associations with metabolic and inflammatory markers. Pediatr Obes. 2021 Mar;16(3):e12729. doi: 10.1111/ijpo.12729. Epub 2020 Oct 15.
Results Reference
derived
PubMed Identifier
29718281
Citation
Han JC, Reyes-Capo DP, Liu CY, Reynolds JC, Turkbey E, Turkbey IB, Bryant J, Marshall JD, Naggert JK, Gahl WA, Yanovski JA, Gunay-Aygun M. Comprehensive Endocrine-Metabolic Evaluation of Patients With Alstrom Syndrome Compared With BMI-Matched Controls. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2707-2719. doi: 10.1210/jc.2018-00496.
Results Reference
derived
PubMed Identifier
26210388
Citation
Radin RM, Tanofsky-Kraff M, Shomaker LB, Kelly NR, Pickworth CK, Shank LM, Altschul AM, Brady SM, Demidowich AP, Yanovski SZ, Hubbard VS, Yanovski JA. Metabolic characteristics of youth with loss of control eating. Eat Behav. 2015 Dec;19:86-9. doi: 10.1016/j.eatbeh.2015.07.002. Epub 2015 Jul 18.
Results Reference
derived
Links:
URL
http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1998-CH-0111.html
Description
NIH Clinical Center Detailed Web Page

Learn more about this trial

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

We'll reach out to this number within 24 hrs